Reviewer's report

Title: Designing and implementing a social protection intervention to enhance TB control: operational evidence from the CRESIPT project in Lima, Peru

Version: 4 Date: 1 March 2015

Reviewer: Cesar Ugarte-Gil

Reviewer's report:

Interesting paper about an important topic in Tuberculosis control. There are my revisions:

Major Compulsory Revisions:

Ethical issues: I'm pretty sure CRESIPT has IRB approval, however should be stated because the intervention has some risks to the participants.

Minor Essential Revisions:

Sample size and population: How the authors decide to stop in 148 participants? These consecutive patients are all the same (pulmonary and full-sensitive TB) or there are also MDR-TB patients, extra-pulmonary patients, HIV-TB patients. If is a mix of patients here, can you explain how this affect the calculation of cost and consequently the value of cash transfer?. Also could be interesting to see how many percentage of TB patients with comorbidities such as diabetes and/or drug abuse your expect and how this affect the value of cash transfer.

Percentages and number of people didn't participate: The authors said in page 8 in Results part: "17/148 (11%) patients declined to participate, died prior to recruitment, or were recruited and subsequently lost to follow up", I suggest to put the number and percentage in each category, to have a better idea of the people who didn't participate. If is possible a flowchart can help.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests